Displaying drugs 12326 - 12350 of 12844 in total
SIG-207
SIG-207 is a Cultured human retinal pigment epithelial cells (ARPE-19) genetically modified with a non-viral vector to express Human alpha-galactosidase A (alpha-Gal A), encapsulated within two-layer modified alginate spheres
Investigational
QXL138AM
QXL138AM is a masked immunocytokine (MIC) comprised of an anti-CD138 immunoglobulin G1 antibody fused to interferon alpha 2a. It binds the CD138 protein on the surface of the tumour cells.
Investigational
mRNA-3745
mRNA-3745 is a lipid nanoparticle (LNP) encapsulated with nucleoside-modified, codon-optimized mRNAs encoding human glucose 6-phosphatase (G6Pase).
Investigational
PVX-410 component XBP1 US184-192(YISPWILAV)
Investigational
PVX-410 component CD138 260-268(GLVGLIFAV)
Investigational
MB-107
MB-107 consists of mobilized peripheral blood-derived autologous CD34+ hematopoietic stem cells that are genetically modified to express the IL2RG gene.
Investigational
B7-H3-specific chimeric antigen receptor T cells
Investigational
DCVAC/OvCa
DCVAC/OvCa is a therapy comprising autologous dendritic cells pulsed with killed ovarian cancer cells and matured by TLR3 ligand ex vivo. It is under investigation for the treatment of ovarian cancer.
Investigational
PEP0101
PEP0101 is a nanocomplex consisting of elastin-like polypeptides and a small interfering RNA (siRNA) designed to down-regulate the expression of EVI1 oncogene in cancer cells.
Investigational
SPL84-23-1
SPL84-23-1 is a sodium salt of 19-bp single-stranded RNA uniformly modified 2'-O-(2-methoxyethyl) phosphorothioate Antisense Oligonucleotide (ASO) consisting of 19 nucleotide residues with the sequence 5'-5MeC-5MeU-G-5MeC-A-A-5MeC-A-G-A-5MeU-G-G-A-A-G-A-5MeC-5MeU-3'
Investigational
PBFT02
PBFT02 is a non-replicating recombinant adeno-associated virus serotype 1 vector delivering human GRN gene encoding the protein progranulin.
Investigational
scAAV9.U7.ACCA
scAAV9.U7.ACCA is a non-replicating recombinant adeno-associated virus vector containing 4 antisense sequences designed to target exon 2 in the human DMD gene under the control of U7 small nuclear non-coding RNA. Developed by Nationwide Children’s Hospital, it is being investigated for the treatment of Duchenne muscular dystrophy.
Investigational
Afamitresgene autoleucel
Afamitresgene autoleucel is a specific Peptide Enhanced Affinity Receptor T cell product comprised of autologous CD4 and CD8 positive T cells genetically engineered with an affinity-enhanced T cell receptor to target cancer-testis antigen MAGE-A4
Investigational
TPX-4589
TPX-4589 is an antibody-drug conjugate composed of a humanized monoclonal antibody targeting CLDN18.2 and linker-payload MC-VC-PAB-MMAE.
Investigational
ISTH0036
ISTH0036 is a synthetic 14-mer phosphorothioate antisense oligonucleotide directed against TGF-beta2 mRNA
Investigational
AAV9/MFSD8
AAV9/MFSD8 is a gene therapy developed by Neurogene Inc. It is an adeno-associated virus serotype 9 (AAV9) vector with an engineered transgene encoding the human CLN7/MFSD8 gene for expression of active human major facilitator superfamily domain containing 8. It was investigated for the treatment of neuronal ceroid lipofuscinosis type 7.
Investigational
WU-CART-007
WU-CART-007 consists of allogeneic, fratricide-resistant genetically modified T cells transduced with a 2nd generation 4-1BB-CD3z chimeric antigen receptor targeting human CD7.
Investigational
CMG901
CMG901 is an anti-Claudin 18.2 monoclonal antibody conjugated with MMAE payload.
Investigational
CTX120
CTX120 is an allogeneic CRISPR/Cas9-mediated genetically modified CAR T cell therapy targeting B-cell maturation antigen.
Investigational
CTX110
CTX110 is an allogeneic CRISPR/Cas9-mediated genetically modified CAR T cell therapy targeting CD19 antigen.
Investigational
Displaying drugs 12326 - 12350 of 12844 in total